Works by Corboy, John R.

Results: 28

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.

Published in:

Frontiers in Neurology, 2022, v. 12, p. 1, doi. 10.3389/fneur.2021.799138

By:

Vollmer, Brandi L.;
Wolf, Andrew B.;
Sillau, Stefan;
Corboy, John R.;
Alvarez, Enrique

Publication type:

Article

Effects of Vestibular Rehabilitation on Multiple Sclerosis-Related Fatigue and Upright Postural Control: A Randomized Controlled Trial.

Published in:

Physical Therapy, 2011, v. 91, n. 8, p. 1166, doi. 10.2522/ptj.20100399

By:

Hebert, Jeffrey R.;
Corboy, John R.;
Manago, Mark M.;
Schenkman, Margaret

Publication type:

Article

Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review.

Published in:

JAMA Neurology, 2024, v. 81, n. 11, p. 1210, doi. 10.1001/jamaneurol.2024.3062

By:

Hua, Le H.;
Solomon, Andrew J.;
Tenembaum, Silvia;
Scalfari, Antonio;
Rovira, Àlex;
Rostasy, Kevin;
Newsome, Scott D.;
Marrie, Ruth Ann;
Magyari, Melinda;
Kantarci, Orhun;
Hemmer, Bernhard;
Hemingway, Cheryl;
Harnegie, Mary Pat;
Graves, Jennifer S.;
Cohen, Jeffrey A.;
Bove, Riley;
Banwell, Brenda;
Corboy, John R.;
Waubant, Emmanuelle

Publication type:

Article

Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience.

Published in:

2024

By:

Wolf, Andrew B.;
Alvarez, Enrique;
Corboy, John R.

Publication type:

Letter

Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?

Published in:

2021

By:

Strijbis, Eva M. M.;
Kerbrat, Anne;
Corboy, John R.

Publication type:

Opinion

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Published in:

JAMA Neurology, 2021, v. 78, n. 1, p. 48, doi. 10.1001/jamaneurol.2020.2950

By:

Cree, Bruce A. C.;
Goldman, Myla D.;
Corboy, John R.;
Singer, Barry A.;
Fox, Edward J.;
Arnold, Douglas L.;
Ford, Corey;
Weinstock-Guttman, Bianca;
Bar-Or, Amit;
Mientus, Susanne;
Sienkiewicz, Daniel;
Zhang, Ying;
Karan, Rajesh;
Tenenbaum, Nadia

Publication type:

Article

TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury.

Published in:

Cells (2073-4409), 2023, v. 12, n. 13, p. 1734, doi. 10.3390/cells12131734

By:

Shafit-Zagardo, Bridget;
Sidoli, Simone;
Goldman, James E.;
DuBois, Juwen C.;
Corboy, John R.;
Strittmatter, Stephen M.;
Guzik, Hillary;
Edema, Ukuemi;
Arackal, Anita G.;
Botbol, Yair M.;
Merheb, Emilio;
Nagra, Rashed M.;
Graff, Sarah

Publication type:

Article

How the Conflict between American Psychiatry and Neurology Delayed the Appreciation of Cognitive Dysfunction in Multiple Sclerosis.

Published in:

Neuropsychology Review, 2009, v. 19, n. 3, p. 399, doi. 10.1007/s11065-009-9089-y

By:

Butler, Michelle A.;
Corboy, John R.;
Filley, Christopher M.

Publication type:

Article

Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.

Published in:

PLoS ONE, 2018, v. 13, n. 2, p. 1, doi. 10.1371/journal.pone.0192109

By:

Hassani, Asma;
Corboy, John R.;
Al-Salam, Suhail;
Khan, Gulfaraz

Publication type:

Article

EFFECTS OF VESTIBULAR REHABILITATION ON MULTIPLE SCLEROSIS-RELATED FATIGUE AND UPRIGHT POSTURAL CONTROL: A RANDOMIZED CONTROLLED TRIAL.

Published in:

International Journal of MS Care, 2011, v. 13, n. 4, p. 200

By:

Hebert, Jeffrey R.;
Corboy, John R.;
Manago, Mark M.;
Schenkman, Margaret

Publication type:

Article

HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity.

Published in:

Journal of NeuroVirology, 2001, v. 7, n. 3, p. 235, doi. 10.1080/13550280152403281

By:

Ross, Heather L.;
Gartner, Suzanne;
McArthur, Justin C.;
Corboy, John R.;
McAllister, John J.;
Millhouse, Scott;
Wigdahl, Brian

Publication type:

Article

DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.

Published in:

Multiple Sclerosis Journal, 2025, v. 31, n. 2, p. 159, doi. 10.1177/13524585241303489

By:

Corboy, John R;
Fox, Robert J;
Cutter, Gary;
Engebretson, Eric;
Miller, Aaron;
Morgan, Charity;
Gustafson, Tarah;
Goodman, Andrew D;
Kannan, Meena;
Sriram, Subramanian;
Xia, Zongqi;
Lynch, Sharon;
Bowen, James;
Kister, Ilya

Publication type:

Article

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – Commentary.

Published in:

Multiple Sclerosis Journal, 2017, v. 23, n. 9, p. 1192, doi. 10.1177/1352458517717809

By:

Corboy, John R.

Publication type:

Article

Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1593, doi. 10.1177/1352458515569101

By:

Solomon, Andrew J.;
Klein, Eran P.;
Corboy, John R.;
Bernat, James L.

Publication type:

Article

Changing Paradigms in MS Therapies.

Published in:

Journal of Managed Care Medicine, 2014, v. 17, n. 1, p. 16

By:

Corboy, John R.

Publication type:

Article

Intrapleural Tetracycline for Recurrent Pneumothorax.

Published in:

1991

By:

Corboy, John R.

Publication type:

Letter

The Nature of Verbal Memory Impairment in Multiple Sclerosis: A List-Learning and Meta-analytic Study.

Published in:

Journal of the International Neuropsychological Society, 2013, v. 19, n. 9, p. 995, doi. 10.1017/S1355617713000957

By:

Lafosse, Jose M.;
Mitchell, Sandra M.;
Corboy, John R.;
Filley, Christopher M.

Publication type:

Article

Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Published in:

2021

By:

Piquet, Amanda L.;
Corboy, John R.;
Vollmer, Timothy L.

Publication type:

Letter

Shifting patterns of multiple sclerosis treatment in a highly prevalent United States population.

Published in:

Annals of Clinical & Translational Neurology, 2024, v. 11, n. 6, p. 1526, doi. 10.1002/acn3.52069

By:

Kwon, Sue;
Sillau, Stefan;
Corboy, John R.;
Nair, Kavita V.;
Carlson, Aaron M.

Publication type:

Article

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis.

Published in:

Annals of Clinical & Translational Neurology, 2023, v. 10, n. 4, p. 579, doi. 10.1002/acn3.51745

By:

Barrera, Britney;
Simpson, Haley;
Engebretson, Eric;
Sillau, Stefan;
Valdez, Brooke;
Parra‐González, José;
Winger, Ryan C.;
Epperson, Lou Anne;
Banks, Ashley;
Pierce, Kathryn;
Spotts, Melanie;
O'Gean, Katie;
Alvarez, Enrique;
Gross, Robert;
Piquet, Amanda L.;
Schreiner, Teri;
Corboy, John R.;
Pei, Jinglan;
Vollmer, Timothy L.;
Nair, Kavita V.

Publication type:

Article

Serious safety events in rituximab‐treated multiple sclerosis and related disorders.

Published in:

Annals of Clinical & Translational Neurology, 2020, v. 7, n. 9, p. 1477, doi. 10.1002/acn3.51136

By:

Vollmer, Brandi L.;
Wallach, Asya I.;
Corboy, John R.;
Dubovskaya, Karolina;
Alvarez, Enrique;
Kister, Ilya

Publication type:

Article

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.

Published in:

Annals of Clinical & Translational Neurology, 2020, v. 7, n. 9, p. 1466, doi. 10.1002/acn3.51111

By:

Vollmer, Brandi L.;
Nair, Kavita;
Sillau, Stefan;
Corboy, John R.;
Vollmer, Timothy;
Alvarez, Enrique

Publication type:

Article

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.

Published in:

Annals of Clinical & Translational Neurology, 2019, v. 6, n. 2, p. 252, doi. 10.1002/acn3.700

By:

Vollmer, Brandi L.;
Nair, Kavita V.;
Sillau, Stefan;
Corboy, John R.;
Vollmer, Timothy;
Alvarez, Enrique

Publication type:

Article

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate.

Published in:

Frontiers in Neurology, 2020, v. 11, p. N.PAG, doi. 10.3389/fneur.2020.01045

By:

Honce, Justin M.;
Nair, Kavita V.;
Hoyt, Brian D.;
Seale, Rebecca A.;
Sillau, Stefan;
Engebretson, Eric;
Schurr, Brittany;
Corboy, John R.;
Vollmer, Timothy L.;
Alvarez, Enrique

Publication type:

Article

Emerging therapies for treatment of multiple sclerosis.

Published in:

Journal of Inflammation Research, 2010, v. 3, p. 53

By:

Corboy, John R.;
Miravalle, Augusto A.

Publication type:

Article

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Published in:

Neuro-Oncology, 2016, v. 18, p. ii13, doi. 10.1093/neuonc/nov291

By:

Blakeley, Jaishri O.;
Coons, Stephen Joel;
Corboy, John R.;
Leidy, Nancy Kline;
Mendoza, Tito R.;
Wefel, Jeffrey S.

Publication type:

Article

Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Published in:

2021

By:

Piquet, Amanda L.;
Corboy, John R.;
Vollmer, Timothy L.

Publication type:

Letter

Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple Sclerosis.

Published in:

Frontiers in Physiology, 2018, p. N.PAG, doi. 10.3389/fphys.2018.01404

By:

Gould, Jeffrey R.;
Reineberg, Andrew E.;
Cleland, Brice T.;
Knoblauch, Kristi E.;
Clinton, Grace K.;
Banich, Marie T.;
Corboy, John R.;
Enoka, Roger M.

Publication type:

Article